Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients (Q27851470)

3

object named as

R L Milne

0 references

author name string

D Caronia

1

0 references

M Zalacain-Díez

4

0 references

G Pita

5

0 references

M R Alonso

6

0 references

L T Moreno

7

0 references

L Sierrasesumaga-Ariznabarreta

8

0 references

J Benítez

9

0 references

A González-Neira

The Pharmacogenomics Journal

10

0 references

publication date

October 2009

0 references

published in

0 references

volume

9

0 references

page(s)

347-53

0 references

issue

5

0 references

cites work

Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy

1 reference

https://api.crossref.org/works/10.1038/TPJ.2009.19

Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells

20 April 2017

1 reference

https://api.crossref.org/works/10.1038/TPJ.2009.19

Polymorphisms in the human XPD (ERCC2) gene, DNA repair capacity and cancer susceptibility: an appraisal

20 April 2017

1 reference

https://api.crossref.org/works/10.1038/TPJ.2009.19

Biology and therapeutic advances for pediatric osteosarcoma

20 April 2017

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.19

Primary bone osteosarcoma in the pediatric age: state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.19

Chemotherapy resistance in osteosarcoma: current challenges and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.19

Molecular mechanisms of resistance and toxicity associated with platinating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.19

Repair of cisplatin--DNA adducts by the mammalian excision nuclease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.19

DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.19

XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.19

A review of clinical and molecular prognostic factors in osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.19

Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.19

Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.19

Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.19

Combinations of polymorphisms in XPD, XPC and XPA in relation to risk of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.19

Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.19

A new xeroderma pigmentosum group C poly(AT) insertion/deletion polymorphism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.19

Modulation of DNA damage/DNA repair capacity by XPC polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.19

Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.19

ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.19

ERCC4Associated with Breast Cancer Risk: A Two-Stage Case-Control Study Using High-throughput Genotyping

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.19

Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with Stage I to II head-and-neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.19

Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.19

21 January 2018

Identifiers

DOI

10.1038/TPJ.2009.19

1 reference

Consolidated OpenCitations Corpus – April 2017

Dimensions Publication ID

1895499

1052063828

0 references

1895499

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference